Cancer immunotherapy is a promising antitumor approach, whereas nontherapeutic side
effects, tumor microenvironment (TME) intricacy, and low tumor immunogenicity limit its …

As the most abundant white blood cells in humans, neutrophils play a key role in acute and
chronic inflammation, suggesting that these cells are a key component of targeted therapies …

T lymphocytes served as immune surveillance to suppress metastases by physically
interacting with cancer cells. Whereas tumor immune privilege and heterogeneity protect …

Tumor recurrence and metastasis still greatly limit the therapeutic efficiency on the majority
of postoperative clinical cases. With the aim to realize more powerful treatment outcomes on …

Immunotherapy has emerged as a promising therapeutic strategy for cancer therapy.
However, the therapeutic efficacy has been distracted due to poor immunogenicity and …

Cutaneous melanoma (CM) is one of the most life-threatening tumors. Although targeted
therapies and immune checkpoint inhibitors have significantly improved patient outcomes …

Ascomylactam C (AsC) is a new 13-membered-ring macrocyclic alkaloid, which was first
isolated and identified in 2019 from the secondary metabolites of the mangrove endophytic …

Immunogenic cell death (ICD) is a type of regulated cell death that can activate adaptive
immune response, and its ability to reshape the tumor microenvironment via multiple …

Abstract Interleukin‐2 (IL‐2) is one of the first FDA‐approved immunotherapeutics, but its
use is limited by toxicity and low efficacy. In addition, all immunotherapies are limited by the …

Background: Immunogenic cell death (ICD) is a form of regulated cell death (RCD) which
could drive the activation of the innate and adaptive immune responses. In this work, we …